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Abstract	  	  The	  human	  Torque	  Teno	  Virus	  Viral	  Protein	  3	  (TTV	  VP3)	  has	  been	  shown	  to	  induce	  apoptosis	  in	  cancer	  cell	  lines	  via	  a	  p53-­‐independent	  pathway	  similar	  to	  its	  homolog	  Apoptin,	  demonstrating	  its	  potential	  as	  a	  cancer	  therapeutic.	  Apoptin	  forms	  aggregates	  in	  the	  nucleus	  while	  TTV	  VP3	  localizes	  in	  the	  cytoplasm.	  In	  order	  to	  determine	  whether	  TTV	  VP3	  forms	  multimers	  like	  Apoptin	  and	  if	  multimerization	  is	  essential	  for	  apoptosis	  induction,	  GFP	  and	  FLAG-­‐tagged	  VP3	  constructs	  were	  created	  and	  transfected	  into	  the	  lung	  cancer	  H1299	  cell	  line	  and	  analyzed	  for	  TTV	  VP3	  protein	  interaction	  by	  co-­‐immunoprecipitation	  studies.	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Introduction	  _________________________________________________________________________________________________	  	  
TTV	  Background	  	  
Although the human Torque Teno Virus (TTV) was discovered in 1997, little is 
still understood about its function and pathogenicity. Initially discovered in Japanese 
patients exhibiting hepatitis symptoms who tested positive for known hepatitis viruses, 
TTV (also known as Transfusion Transmitted Virus) was thought to be responsible for 
liver disease and cirrhosis. Later tests indicated that different strains of TTV are present 
in over 90% of the populations in most countries, with a higher prevalence in patients 
with liver disease [3]. There is no proven correlation between TTV and the onset of liver 
problems, but transfusion patients and liver patients proved to have a higher viremia than 
healthy individuals. One study argues that co-infection of TTV and Hepatitis E Virus 
promotes advancement of hepatic inflammatory responses but that severe liver disease 
suppresses TTV infection [2]. This unusual behavior of TTV in vivo is not well 
understood. However, the responsiveness of TTV to damaged cells, and the fact that viral 
replication (but perhaps no other viral protein function) is hindered, could indicate the 
virus’s sensitivity to apoptotic cellular pathways. The peculiar commensal behavior with 
human cells, especially in the liver, and Hepatitis E, as well as the sensitivity to damaged-
cell pathways, make TTV an interesting subject for cancer therapy research.  
TTV	  Genomics	  and	  Classification	  	  
In an effort to understand the prevalence and clinical effects of TTV, researchers 
are focusing on TTV’s genetics and molecular behavior. Through a study conducted by 
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Simmonds, et al, it was determined that TTV is a non-enveloped virus with a single 
stranded DNA (ssDNA) genome [14]. This and other studies proved the high stability of 
the virus, showing it could withstand conditions in the bile, Tween 80 treatment, high 
temperatures, and detergents, likening TTV to parvoviruses [3].  Initial DNA studies 
suggested the genome was linear, until it was discovered that a GC-rich area on each 
extremity forms a circular molecule [12]. Because of the similarities to both parvoviruses 
and circoviruses, the taxonomy of TTV has changed within the last few decades. As of 
2006, it is considered a part of the anellovirus family [11], a viral family consisting 
entirely of the TTVs of different species, including the human Torque Teno Virus [1].   
Even within the human Torque Teno Virus (hTTV) classification, there are high 
levels of genetic variability: there are 38 known genotypes that have been further 
classified into one of five phylogenetic groups [12]. This is unusual for a virus with only 
3.8 kb and unknown pathogenicity. While there is only 60% homology among the 
genotypes, the three open reading frames (ORFs) are conserved 70-100% within each 
strain; they code for viral proteins 1, 2, and 3 (VP1-3) respectively. It is believed that 
VP1 is involved in the construction of the viral capsid. ORF1 contains several conserved 
replicase protein motifs and is highly basic near its N‐terminus, two qualities which 
Noteborn et al determined to be present in circoviral capsid protein formation. The 
protein encoded by ORF2, VP2, is less understood, but as it is similar in sequence to VP2 
of the chicken anemia virus (CAV) which is classified as a structural scaffold protein, it 
is likely the TTV VP2 is also involved in a scaffold pathway or structural assembly. VP3, 
the focus of this particular study, is coded by ORF3 and is considerably smaller than VP1 
and VP2.  
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Comparison	  to	  the	  Chicken	  Anemia	  Virus	  
These ORFs and resulting viral proteins are very similar to those of the Chicken 
Anemia Virus (CAV), a circovirus that is known for its viral protein 3 (VP3), nicknamed 
Apoptin. Apoptin has shown to induce apoptosis in cancer cells independent of a p53 
pathway while leaving primary cells intact [7]. P53 is a tumor suppressor that initiates a 
DNA repair pathway for damaged cells by arresting the cell cycle between the G1 and S 
phases. This protein is often the target of cancer therapies as it has the ability to induce 
apoptosis in cells that are severely damaged. Cancer cells, however, often have 
dysfunctional p53, if the protein is present at all, making many of these p53-targeted 
cancer therapies obsolete. Apoptin is able to induce apoptosis regardless of p53 presence 
in cancer cells, making it highly interesting for broad-spectrum cancer research.  
Apoptin localizes in the nucleus of cancer cells and then forms multimers, a 
function that somehow induces the apoptosis of the cancer cell. Previous studies have 
suggested the nuclear localization sequence (NLS) and nuclear export sequence (NES) 
are directly involved in inducing cellular apoptosis, and that the shuttling of Apoptin into 
the nucleus stimulates the apoptotic induction pathway [7]. However, other Apoptin 
homologs, such as Porcine Circovirus 1 VP3 (PCV VP3) and TTV VP3, localize in the 
cytoplasm [4], suggesting the NLS/NES signaling may not be as critical in the apoptosis-
inducing process.  
TTV VP3, containing 105 amino acids in the TA278 TTV strain, demonstrates 
significant functional similarity to Apoptin. TTV VP3 has also been referred to as TAIP, 
or TTV-derived apoptosis inducing protein [8], since it also induces apoptosis in cancer 
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cells via a non-p53-dependent pathway, although to a lesser extent than Apoptin [7]. 
While TTV VP3 localizes in the cytoplasm of infected cells, like PCV VP3, Apoptin 
localizes in the nucleus. However, the apoptotic effect of both Apoptin and TTV VP3 and 
their protein structure similarities suggests that they might induce apoptosis in cancer 
cells through similar cellular pathways. Both Apoptin and TTV VP3 induce onco-specific 
apoptosis, but they localize in different areas. Determining whether these two proteins 
have any functional similarities earlier on in the induction pathway could lead to cancer 
therapeutic targets in the future. 
Multimerization	  	  
Heilman, et.al. determined that Apoptin multimerizes varyingly in different 
cancer cell lines and suggested that these multimer aggregates contribute to Apoptin’s 
ability to induce apoptosis and localize in the nucleus [7]. Overlapping Apoptin’s NES 
(amino acids 33-46) is a multimerization domain that allows Apoptin to form multimers 
of about 30 units in the H1299 cell line [9]. Leliveld, et.al. suggested that the Apoptin 
monomer forms beta-turns with alternating hydrophobic and hydrophilic residues, a motif 
that would provide ample opportunity for intermolecular interactions. This simple 
secondary structure remarkably allows for the multimerization complex to form, which 
can then interact with intracellular signals and perhaps induce apoptosis [9].  
Previous TTV VP3 studies, particularly the initial WPI project conducted by 
Evan-Browning and Orme-Johnson in 2009, observed that TTV VP3 tagged with GFP 
also formed bright aggregates of varying sizes in the cytoplasm of H1299 cells [6]. These 
aggregates were oriented close to the nucleus but did not diffuse past the nuclear 
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membrane. Their size and shape were described as both asymmetric and circular, and 
both diminutive and largely obtrusive. As suggested by Evan-Browning and Orme-
Johnson, this seemingly sporadic aggregate formation could either be the result of 
random weak protein-protein interactions, driven solely by the high concentration of 
expressed TTV VP3, or the result of a particular secondary structure that creates a 
multimerization domain.  
Given the behavioral similarities, but the localization differences, of Apoptin and 
TTV VP3, determining whether TTV VP3 also multimerizes like Apoptin does could 
suggest that the multimerization process is essential for inducing apoptosis. Discovering 
additional similarities between these two proteins could also further the evolutionary 
understanding of these two viruses (and other circoviruses) and their potential function as 
cancer therapeutics. This project will explore TTV VP3’s multimerization capacity and 
how it relates to Apoptin’s multimerization process in an effort to understand the 
apoptotic pathway that both proteins induce.  
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Materials	  and	  Methods	  _________________________________________________________________________________________________	  
pEGFP+	  TTV	  VP3	  Vector	  Amplification	  
pEGFP vector was used to transform NEB 10-beta competent cells (C3019I). 5µL of the 
vector sample was added to 100µL of the high-efficiency competent cells and allowed to 
incubate on ice for 10 minutes. The mixture was then heat shocked for 20 seconds at 
42°C and placed back on ice for 3 minutes. 900uL of LB broth containing 1X kanamycin 
was added and the tube was incubated at 37°C on a rotator for 45 minutes. 200µL of the 
transformation was then plated on a kanamycin agar plate and allowed to incubate 
overnight at 37°C. Using a sterile pipet tip, one of the resulting colonies was picked and 
rescreened on a second kanamycin agar plate and allowed to incubate at 37°C, upside 
down, overnight in order to separate positive colonies from satellite colonies. The 
following day, one large colony was inoculated into 250mL of LB broth containing 1X 
kanamycin and incubated at 37°C overnight on the shaker. The Promega Midi-Prep Kit 
was then used to extract the pEGFP TTV VP3 plasmid. In order to discern whether the 
resulting extraction contained the desired plasmid, a double digest was conducted on 3µL 
of the sample using BamH1 and EcoR1. After an hour of incubation at 37°C, the digests 
were resolved on a 0.9% agarose gel at 90V and post-stained with ethidium bromide to 
visualize the bands. 
3X	  FLAG	  Plasmid	  Construction	  
Vector	  Components	  
A Promega pGEM-T construct containing the TTV VP3 gene of interest was double 
digested with 1 µL of BamH1 and EcoR1 each. A 3X FLAG vector containing a porcine 
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circovirus gene was also double digested with 1 µL of BamH1 and EcoR1. Both digests 
were allowed to incubate at 37°C for an hour and were then resolved on a 0.9% agarose 
gel at 90V. Post-staining with ethidium bromide was done in order to visualize the bands 
on the gel. The 3X FLAG vector bands and the TTV VP3 insert bands were excised from 
the gel and purified using Promega’s PCR Clean-up Kit.  
 
Transformation	  &	  Colonization	  
Ligations of the TTV VP3 insert and the 3X FLAG vector were performed in 
quadruplicate using T4 DNA Ligase and DNA Ligase Buffer, with the insert in excess 
(6µL) and the vector in limiting (1µL) quantity. The ligations were stored overnight at 
4°C.  Each ligation reaction was transferred into 100µL of Pro-5 alpha JM109 competent 
cells and incubated on ice for 15 minutes in order to form DNA complexes.  The cells 
underwent heat shock for 45 seconds before being put on ice for 3 minutes. One negative 
control of JM109 cells was made without any DNA transformation and two other 
negative controls of JM109 cells were made using junk DNA from previously failed 
ligation reactions. 900µL of LB broth was added to each transformed and negative 
control tubes, which were then incubated at 37°C on a rotator for 45 minutes. 200µL of 
each competent cell mixture was spread on separate ampicillin agar plates and allowed to 
incubate upside down for 24 hours. Large colonies were inoculated with a sterile pipet tip 
into 3mL of LB broth containing ampicillin. Two colonies were taken from each plate, 
resulting in 8 inoculated cultures. The culture tubes were put on the shaker at 37°C for 24 
hours to encourage culture growth. 
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3X	  FLAG+TTV	  VP3	  Extraction	  and	  Amplification	  
A total of 8 plasmid DNA extraction procedures were done using Promega’s Mini-Prep 
Kit. Each extraction produced 30µL of purified plasmid DNA extract. To determine 
whether this purified plasmid was our 3X FLAG construct containing the TTV VP3 gene 
of interest, a double restriction digest was done on 3µL of each sample using 1 µL of 
BamH1 and EcoR1 each. After an hour of incubation, the digested samples were resolved 
on a 0.9% agarose gel at 90V and post-stained with ethidium bromide to visualize the 
bands.  
Each of the 8 samples showed positive results, but 3 samples with the best bands were 
chosen to amplify our construct. Using the dregs of the cultures used for the Mini-Prep, 
the competent cells containing our desired 3X FLAG construct were inoculated into 
100mL of LB broth containing ampicillin in a large Erlenmeyer flask and put on the 
shaker at 37°C for 24 hours. Each culture showed sufficient growth and the construct was 
extracted using Promega’s Midi-Prep Kit following the centrifugation protocol. These 
extractions resulted in three 600µL samples of plasmid DNA. To discern that these 
extractions contained our desired 3X FLAG and TTV VP3 construct, a double digest was 
performed on 5µL of each sample using 1 µL of BamH1 and EcoR1 each. After an hour 
of incubating at 37°C, the digests were resolved on a 0.9% agarose gel at 90V and post-
stained with ethidium bromide to visualize the bands. Once bands were visualized, the 
samples were sent to the lab to be sequenced. 
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Maintaining	  H1299	  Cell	  Culture	  
H1299 lung cancer stock cells were suspended in D10 media (DEMEM-HEPES, fetal 
bovine serum, glutamine, gentamicin) in growth-enhanced T-25 tissue culture flasks and 
kept at 37ºC for optimal growth. Once the cells had adhered to the flask and had reached 
80% confluence, the D10 media was aspirated and the cells were washed with 2 mL of 
PBS. Trypsin (1mL) was added to the flask and curtained over the cells 5-10 times before 
being quickly aspirated. After approximately four minutes, the cells were visualized 
under the microscope to insure they were no longer adhered to the flask and were then 
resuspended in 5mL of warm D10 by gently pipetting the media up and down. An aliquot 
of the resuspended cells (0.5-1mL) was then transferred to a new T-25 flask and 5-6mL 
of fresh D10 was added. The new flask containing the resuspended cells was then placed 
in the 37ºC incubator to optimize the H1299 cell growth, and the passage process was 
repeated every 2-3 days when cells reached 80% confluence. 
Wild	  Type	  TTV	  VP3	  Transfection	  &	  Harvest	  
In order for the wt TTV VP3 fusion proteins to be analyzed in cancer cell conditions, the 
3X FLAG and GFP TTV VP3 constructs were transfected into the H1299 cells. 
Following Qiagen’s transfection protocol for 100mm plates, cells were passed one day 
prior to transfection and were transfected about 24 hours later when they had reached 40-
60% confluence. In order to optimize the transfection efficiency, 4µg of each TTV VP3 
construct was used instead of the recommended 2µg DNA total. 24-48 hours post-
transfection the cells were visualized with the fluoroscope to verify the expression of the 
GFP TTV VP3 fusion protein. The cells were then harvested by aspirating the D10, 
washing in PBS, scraping the cells, and resuspending them in 200µL of PBS. The cell 
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suspension was added to an Eppendorf tube and spun down (1500g for 3 minutes) to 
create a cell pellet. The PBS supernatant was discarded, then 100µL of lysis Buffer X 
(pH 8.5) was pipetted gently to break apart the pellet and lyse the cells and was left to 
incubate for 15 minutes. The cell extract sample was then clarified by centrifugation 
(1500g for 5 minutes) to precipitate insoluble lipids and other heavy cell debris. The 
clarified extract (supernatant) was carefully transferred to a fresh tube to be used for 
immunoprecipitation.  
Truncated	  TTV	  VP3	  Transfection	  &	  Harvest	  	  
Following Qiagen’s Effectene protocol for 6 well plates, H1299 cells were transfected 
with the DNA constructs listed in Table 1 (See Tables Section). The cells were harvested 
48 hours post-transfection by collecting the media into a 15mL conical tube, scraping and 
collecting the cells, and washing the remaining cells in PBS and again adding the 
suspension to the conical tube. The six tubes were subjected to centrifugation (1500g for 
5 minutes) to collect the cell pellets, which were then resuspended in 100µL lysis buffer 
X (pH 7.4 + PI) and clarified. The supernatants were transferred to clean Eppendorf tubes 
to be used for immunoprecipitation.  
TTVVP3	  Controls:	  Transfection,	  Harvest	  and	  Fluorimetry	  
 
The above process was repeated using the DNA constructs listed in Table 2 (See Tables 
Section). After lysing the cells with lysis Buffer X (pH 7.4), the fluorescence of each 
sample was read by a fluorescence spectrophotometer scanning from 470-600nm and 
observing behavior at 510nm (the emission peak of GFP) in order to track the presence of 
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GFP fusion proteins in the samples. The fluorescence of the samples was gathered again 
after clarifying the extract and again after immunoprecipitating with the EZview beads. 
FLAG	  Immunoprecipitation	  and	  Western	  Blotting	  
EZview Red ANTI-FLAG M2 Affinity beads were added to the clarified cell extracts 
(10µL were added to extracts from 6 well-plated cells, 15µL were added to extracts from 
100mm-plated cells) and were placed on a rotator at 4°C for four hours. In order to elute 
any bound protein from the affinity beads, the samples were boiled in SDS sample 
loading buffer at 95°C for 5 minutes before being loaded onto a 16% polyacrylamide gel 
alongside a pre-stained 2-log protein ladder. The gel was run at 50V until the samples had 
passed through the stacking gel and then at 70V until the bromophenol blue had reached 
the bottom.  
A transfer sandwich was then assembled using the completed gel and a nitrocellulose 
membrane that had been soaking in transfer buffer. The sandwich was loaded into the 
transfer apparatus and run at a constant 200mA for 1 hour. After disassembling the 
sandwich, the nitrocellulose membrane was put into blocking buffer (TBS-T + 5% 
powdered milk) for 1 hour. The membrane was then washed 5 X 5 minutes with TBS-T 
and then blotted for 1 hour with either a 1:5000 monoclonal mouse anti-GFP (Sigma 
G1546) or 1:5000 mouse anti-FLAG (Sigma F3165) primary antibody diluted in 10mL 
TBS-T. The membrane was washed again 5 X 5 minutes with TBS-T and then blotted for 
1 hour with a 1:5000 polyclonal goat anti-mouse alkaline phosphatase-conjugated 
secondary antibody (Thermo Scientific Prod #31328) dilution in 10mL TBS-T. The blot 
was again washed 5 X 5 minutes in TBS-T and then 2 X 5 minutes with TBS before 
staining with Sigma Fast BCIP/NBT (Sigma B5655) to visualize any bands. 
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Results	  _________________________________________________________________________________________________	  	  
Apoptin has been shown to form multimers in cancer cells, therefore determining 
whether TTV VP3, an Apoptin homolog, also multimerizes in cancer cells would 
elucidate whether this multimerization capacity is a necessary function for these proteins 
to induce onco-specific apoptosis.  In order for TTV VP3 multimerization to be 
investigated using a combination of immunoprecipitation and Western blotting assays, 
fusion protein plasmids were constructed. A pEGFP construct containing the wild type 
TTV VP3 gene was verified by the double restriction profile, which proved the presence 
of a 4000bp pEGFP vector and a 325bp insert when compared against a 2-log DNA 
ladder (Figure 2, lane 9). Given its usefulness in affinity and immunoprecipitation assays, 
and the availability of EZ View anti-FLAG beads, it was decided that a FLAG fusion 
protein would also be constructed by inserting a wild type TTV VP3 sequence into a 3X 
FLAG CMV-Myc 26 vector. Transforming 3X FLAG and TTV VP3 ligations into JM 
109 e. Coli bacteria proved successful, as seen in the BamH1 and EcoR1 restriction 
profile that shows the 6300bp 3X FLAG vector band and the 325bp wt TTV VP3 insert 
band (Figure 1B). Subsequent sequence analysis further verified the presence of the 3X-
FLAG wt TTV VP3 construct with the correct reading frame orientation in each of the 
three midi-prep extractions (Figure 3), confirming it could be properly expressed in cells.  
In order to determine wt TTV VP3’s multimerization capacity in human cancer 
cells in vitro, the pEGFP and 3X-FLAG TTV VP3 constructs were co-transfected into 
human lung cancer H1299 cells. Co-transfection with 2µg of each construct yielded only 
10-15% GFP fusion protein expression when visualized on a fluoroscope. Increasing the 
	   16	  
DNA volume to 4µg of each construct yielded over 80% GFP fusion protein expression 
and therefore successful transfection and GFP TTV VP3 expression. Assuming that TTV 
VP3 multimerizes, co-transfection and therefore co-expression of the fusion proteins 
should yield multimers containing both FLAG and GFP tags. Assuming TTV VP3 does 
not multimerize, both fusion proteins would be expressed but later separated by FLAG-
specific immunoprecipitation (Figure 4). 
Initial co-immunoprecipitation analysis with a monoclonal M2 goat anti-mouse 
secondary antibody (KPL-051806) yielded only faint bands at 100kDa and 50kDa 
(Figure 5). Given the high concentration of the secondary antibody (1500x) that was 
needed in order to produce this background signal, a new secondary antibody (polyclonal 
goat anti-mouse alkaline phosphatase conjugated- Thermo Scientific #31328) was used 
for the subsequent Western blots.  
 When the wild type-transfected IP samples were again blotted for GFP and 
FLAG, broad bands at 24kDa, along with the 100kDa and 50kDa bands, were visualized, 
(Figure 6). Wild type TTV VP3 is 11.6kDa (38.6kDa when fused with GFP and 14kDa 
when fused with 3X FLAG), so these 24, 50, and 100kDa bands are representative of the 
mouse antibody and heavy and light chains from the EZ View beads. Although the 
appearance of this 24kDa band could have been indicating the presence of a GFP-fused 
protein, it was inconclusive to say given the absence of a negative control.  
 In order to determine whether this broad 24kDa band was purely representative of 
the mouse IgG light chain, a TTV VP3 truncation study was conducted. Previous projects 
had produced four TTV VP3 truncations (aa 1-78, aa 79-105, aa 1-60, aa 61-105) inserted 
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into a pEGFP vector. H1299 cells were plated into a 6-well dish and co-transfected 
according to Table 1 (see Tables section). After extracting and immunoprecipitating, the 
samples were run on two 16% SDS-PAGE gels simultaneously and then transferred to a 
nitrocellulose membrane. One membrane was western blotted for anti-GFP and the other 
for anti-FLAG, but other than the differing primary antibodies, the blots were equally 
treated. The anti-GFP blot showed three bands for every sample at 100kDa, 50kDa, and 
24kDa, increasing in intensity. The consistency of these bands, and the fact that the 
negative control (GFP-wt TTV VP3 only) had a strong signal at 24kDa suggested that 
this broad band was in fact just background information coming from the EZ View Beads 
mouse antibodies and was not indicative of GFP’s presence in the IP samples.  
The Western blot results also did not indicate that TTV VP3 does not multimerize 
as there was no distinct band on the anti-FLAG blot at 14kDa (the molecular weight of 
TTV VP3 fused with the 3X FLAG peptide) for any of the samples containing FLAG wt 
TTV VP3. There were indistinct smears or band broadening between 30 and 15kDa, but 
given the lack of a positive input control signal these indistinct bands are still 
inconclusive until 3X FLAG TTV VP3 expression and presence in the IP sample can be 
verified. 
In order to test the functionality of the Western blot procedure and track the 
presence of each TTV VP3 fusion protein, the contents of the 3X FLAG TTV VP3 
construct were confirmed by running another BamH1 and EcoR1 restriction profile and 
four more H1299 cultures were transfected according to Table 2 (see Tables section). In 
order to ascertain the presence of the GFP fusion protein at each step, the samples were 
scanned for fluorescence and GFP emission (510nm) directly after cell lysis, after 
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clarifying the extracts, and after immunoprecipitation. Figure 7 shows the fluorescence 
results of the 3XFLAG-wt TTV VP3 and GFP-aa1-60 TTV VP3 co-transfected sample. 
The clarifying extract shows a slight decrease in emission at 510nm from the lysis 
extract, but, more significantly, the emission peak at 510nm entirely disappears after the 
FLAG IP and follows the same baseline as the 3X FLAG wt TTV VP3 fluorescence 
negative control. 
Resolving these four IPs alongside an Apoptin control (3X FLAG wt and GFP wt 
post-FLAG IP) and blotting for both FLAG and GFP indicated the presence of a 17kDa 
protein in the Apoptin sample on the anti-FLAG blot, but only the usual heavy and light 
chain bands for the other samples on both blots (Figure 8). 
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Discussion	  _________________________________________________________________________________________________	  
 Much remains to be understood about the human Torque Teno Virus. Its 
pathogenicity, if it exists, is still unclear. Originally called the Transfusion Transmitted 
Virus [2], it was believed that TTV somehow caused liver cirrhosis via blood 
transfusions, but given its presence in about 90% of the human population it appears to 
exist complacently in vivo [3]. That being said, the virus easily exists and infects human 
primary cells with seemingly no adverse effects, making it a potentially powerful vector 
for gene therapy, drug delivery, or cancer cell targets.  
 The protein coded by TTV’s ORF3 has proved to induce apoptosis in cancer cells 
similar to its CAV VP3 homolog Apoptin. This apoptotic affect can be visualized directly 
under the microscope; even within 24 hours many of the cultured cancer cells are 
obliterated by TTV VP3 and by Apoptin. The mechanism by which this onco-specific 
cell death is induced is likely similar for both of these proteins given their taxonomical 
homology and consistent cancer-targeting behavior.  
 Earlier studies suggested that Apoptin’s nuclear localization was critical for 
arresting the cell cycle [7], but some of its homologs (TTV VP3 included) localize 
primarily in the cytoplasm and still manage to induce cell death. For this reason the 
concept of protein multimerization was considered to be another element contributing to 
the cell-death signaling pathway. Apoptin was found to exist as 30-40 multi-protein 
complexes by Leliveld et al, and former WPI project studies observed TTV VP3 
aggregating similarly through GFP fluorescence studies [8, 6]. The confirmation of 
Apoptin’s multimerization ability and the determination of its multimerization domain 
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provide us with ample reason to explore whether its hTTV homolog does the same. This 
study sought merely to determine whether TTV VP3 multimerizes at all in vitro H1299 
using similar co-immunoprecipitation assays as Heilman et. al. [8]. Unfortunately, 
however, this particular study could not conclusively say whether TTV VP3 multimerizes 
or not.  
	   Immunoblotting	  failed to both prove and disprove the presence of TTV VP3 
multimers in infected H1299 cells. Theoretically, immunoprecipitation with FLAG EZ 
View beads would pull any FLAG-tagged TTV VP3 out of the clarified H1299 extract. If 
TTV VP3 multimerizes, most if not all multimers complexes would contain some ratio of 
GFP and 3X FLAG-tagged protein, so precipitating FLAG-tagged TTV VP3 would pull 
GFP-tagged TTV VP3 out of solution as well, and blotting for GFP should produce a 
signal (Figure 4). Assuming TTV VP3 does not multimerize or only multimerized with 
the FLAG-tagged proteins, western blotting with an anti-FLAG primary should produce a 
signal. However, blotting for both anti-GFP and anti-FLAG did not produce any evidence 
towards either of these theories. The lack of signal on the anti-GFP blot (Figure 8A) 
suggests GFP TTV VP3 was discarded in solution during the IP step, but the lack of a 
14kDa band (or a higher molecular weight band if only FLAG-tagged TTV VP3s were 
multimerizing, excluding the GFP fusion protein) in Figure 8B suggest that neither of the 
TTV VP3 fusion proteins were precipitated out of solution or able to run through the 16% 
SDS-PAGE gel. 
 Having observed significant fluorescence under the fluoroscope, it is known that 
the GFP-tagged TTV VP3 is definitely expressed in the H1299 cells and begins to induce 
apoptosis before being harvested. It is possible, however, that the 3X FLAG TTV VP3 
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could not be properly expressed in the H1299 cells, although this is would be unusual 
given the results of the sequence analysis (Figure 3), which showed proper insertion and 
alignment of TTV VP3 within the 3X FLAG vector, and, considering that it had been 
freshly constructed, it is unlikely that it had been subjected to degrading nuclease 
activity.  
 Evan-Browning and Orme-Johnson did observe GFP TTV VP3 aggregates with 
the fluoroscope [6], and given the particular affinity of FLAG EZ View beads to 3X 
FLAG fusion proteins, it is also possible that multimer complexes exist and that 
something about its structure prevents it from being analyzed with this particular 
protocol. For example, Apoptin’s multi-protein complex has been shown to fall out of 
solution with the insolubles during the clarifying step post-cell lysis (unpublished 
observation). It is possible that TTV VP3 complexes also fall out of solution with 
insoluble proteins, but given the intensity of the GFP emission after the clarifying step, 
we know that GFP TTV VP3 is kept in solution. If the GFP TTV VP3 is indeed 
multimerizing, it is not falling out of solution before the immunoprecipitation step, but it 
is still possible that multimers containing the 3X FLAG TTV VP3 are insoluble. 
If multi-protein complexes are small enough or soluble enough to stay in solution 
and they are still not being detected, it is possible that something is preventing the EZ 
View beads’ anti-FLAG from binding to the 3X FLAG epitope. Perhaps the structure of 
the multi-protein complex is arranged in such a way that the cumbersome 27kDa GFP tag 
is blocking access to the 3X FLAG tag. It is also possible that the 3X FLAG construct is 
simply not being expressed. Figure 8 shows that both 3X FLAG TTV VP3 and GFP TTV 
VP3 were not in the IP sample, and the Western blotting was proven to be functional 
	   22	  
given the presence of the 3X FLAG Apoptin band at 17kDa on the FLAG blot. Given the 
fluorescence observations from the fluoroscope and the fluorimeter, the GFP TTV VP3 is 
definitely expressed and harvested and is most likely lost after the IP. This information 
combined with the lack of a 14kDa 3X FLAG TTV VP3 band on the FLAG blots 
suggests that the 3X FLAG TTV VP3 was either discarded in solution after the IP or was 
never expressed in the first place.  
Future	  Experiments	  	  
Given the inconclusiveness of this project, it is highly recommended that the 
protocol be optimized and repeated in order to conclusively determine whether TTV VP3 
multimerizes or not. Verifying the expression of 3X FLAG TTV VP3 in the H1299 cells, 
the affinity of the FLAG EZ View beads to the 3X FLAG tag, and the presence of the 3X 
FLAG fusion protein after the clarifying step would presumably elucidate whether this 
methodology is functional and whether these results are conclusive. 
If subsequent experiments determine that TTV VP3 multimerizes in vitro, the use 
of the available truncations would help ascertain the location of multimerization 
domain(s). Point-mutating within these domains to knock out the multimerization 
capacity could create proteins that exist primarily as monomers. Knocking out the 
multimerization domain in this way and testing for apoptosis induction in transformed 
cells could then suggest whether multimerization is necessary for the cell-death pathway 
to be activated by TTV VP3 and, by extension, Apoptin. Understanding the mechanism 
by which TTV VP3 interacts with itself and whether this interaction is necessary for 
onco-specific apoptosis to be induced would bring us one step closer to understanding 
and harnessing the power of these onco-apoptotic proteins for cancer therapeutics. 
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Tables	  
______________________________________________________________________________________ 
Table 1: Co-transfected H1299 sample descriptions and observations noted 48 hours post-transfection 
(where * indicates average, ** indicates above average, and *** indicates significant observations). 
 
 
 
 
 
 
 
 
 
 
 
 	  
 
Table 2: DNA constructs used to transfect H1299 control samples and apoptosis observations 24 hours 
post-transfection 
 
 
 
 
 
 
 	  
Co-transfection Observed 
Transfection 
Efficiency 
Observed 
Apoptosis 
Observed 
Localization 
3XFLAG-wt TTVVP3 
GFP-wt TTVVP3 
** very high cytoplasm 
GFP-wt TTVVP3 
(Negative control) 
* low cytoplasm 
3XFLAG-wt TTVVP3 
GFP- TTVVP3 aa 1-78 
low low cytoplasm 
3XFLAG-wt TTVVP3 
GFP- TTVVP3 aa 79-105 
*** low whole-cell 
diffusion 
3XFLAG-wt TTVVP3 
GFP-TTVVP3 aa 61-105 
*** *** whole-cell 
diffusion 
3XFLAG-wt TTVVP3 
GFP-TTVVP3 aa 1-60 
*** *** whole-cell 
diffusion 
DNA constructs used Observed 
Apoptosis 
3XFLAG-wt TTVVP3 none 
GFP-wt TTVVP3 
 
low 
3XFLAG-wt TTVVP3 
GFP- TTVVP3 aa 1-60 
high 
3XFLAG-wt TTVVP3 
GFP- wt TTVVP3 
low 
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Figures	  	  
 
Figure 1: (A)-BamH1 and EcoR1 restriction profile of a 3X FLAG PCVVP3 construct and a pGEM-T wt 
TTVVP3 construct. The green circle shows the band of the wt TTV VP3 gene that was collected and used 
as the insert for the 3X FLAG TTVVP3 construct. The blue circle shows the 3X FLAG vector band that 
was needed but not collected due to clumping. (B)- BamH1 and EcoR1 restriction profile of the new 3X 
FLAG wt TTV VP3 construct demonstrating proper inclusion of both the 3X FLAG vector (8000bp) and 
wt TTV VP3 gene (325bp). (C)- Repeat of Figure 1A with a smaller starting volume of the 3X FLAG 
PCVVP3 construct. The vector band (green circle) was collected and used to create the 3X FLAG TTVVP3 
construct seen in Figure 1B.  
 
 
Figure 2: BamH1 and EcoR1 restriction profile of the pEGFP TTV VP3 construct post-amplification 
(Lane 9) with the vector band at 4000bp and the TTV VP3 insert band at about 325bp. 
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Figure 3: Sequence analysis of the 3X FLAG TTV VP3 construct verifying proper insertion of the wt TTV 
VP3 gene with correct reading frame orientation with the 3X FLAG sequence. 
 
 
 
 
 
 
 
 
Figure 4: Schematic of the multimerization and co-immunoprecipitation assay hypothesis.  
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Figure 5: Western blot showing placement of background bands (~100kDa and ~50kDa) when IP samples 
were blotted for GFP. This blot confirmed a functional primary antibody and that lysis Buffer X produced 
less background at a pH of 7.4 
 
 
 
 
Figure 6: Western blot of an immunoprecipitated co-transfected cell extract blotted for GFP (left) and 
FLAG (right). 
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Figure 7: Fluorescence spectra for the 3X FLAG wt TTV VP3 and GFP aa 1-60 TTV VP3 sample. 
Scanned from 470nm to 600nm, the peaks at 510nm indicate the presence of GFP in both the lysis and 
clarified extracts. The spectrum after the IP does not show any GFP emission, suggesting that GFP is no 
longer in the sample or that it is quenched by being tightly packed on the EZ View beads.   	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Figure 8: (A) Blotting control and truncated TTV VP3 samples for GFP. Heavy and light chain bands are 
visible at 55kDa and 25kDa respectively but no other distinct bands are visible except for the Apoptin 
control. (B) Blotting control and truncated TTV VP3 samples for FLAG. Again, heavy and light chain 
bands are visible. There is no indication of FLAG around 14kDa, the size of 3X FLAG-fused TTV VP3, 
while there is a band at 17kDa (white arrow) for the 3X FLAG-Apoptin fusion protein.  
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